Forty patients with post-hepatitis C virus ( HCV ) end-stage liver disease were randomized into two groups : Group @ ( GI ) : @ patients who received granulocyte colony-stimulating factor ( G-CSF ) for @days followed by autologous MSCs peripheral-vein infusion and group @ ( GII ) : @ patients who received regular liver-supportive treatment only ( control group ) .